Candel Therapeutics, Inc. CADL Accretion Of Debt Discount
Accretion Of Debt Discount at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cadl:AccretionOfDebtDiscount.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s accretion of debt discount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s accretion of debt discount?
- Candel Therapeutics, Inc. (CADL) reported accretion of debt discount of $306K in Q1 2026.
- How has Candel Therapeutics, Inc.'s accretion of debt discount changed year-over-year?
- Candel Therapeutics, Inc.'s accretion of debt discount increased by 595.5% year-over-year, from $44K to $306K.
- What is the long-term trend for Candel Therapeutics, Inc.'s accretion of debt discount?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s accretion of debt discount has grown at a 7.4% compound annual growth rate (CAGR), from $291K to $360K.
- What does accretion of debt discount mean?
- This represents the non-cash amortization of the discount on debt instruments, which increases the carrying value of the debt over its term. It reflects the effective interest expense associated with financing arrangements and is added back to net income to determine operating cash flow.